Media stories about Icon Plc (NASDAQ:ICLR) have trended somewhat positive recently, according to AlphaOne Sentiment Analysis. AlphaOne, a subsidiary of Accern, identifies positive and negative news coverage by reviewing more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Icon Plc earned a news sentiment score of 0.16 on AlphaOne’s scale. AlphaOne also gave headlines about the medical research company an impact score of 15 out of 100, indicating that recent news coverage is very unlikely to have an impact on the company’s share price in the near term.
These are some of the headlines that may have impacted Alpha One’s analysis:
- ICON : and DIA Amplify Thought Leadership and Debate with DIA Live 2017 (4-traders.com)
- Icon Plc (ICLR) Rating Lowered to Buy at BidaskClub (americanbankingnews.com)
- ICON and DIA Amplify Thought Leadership and Debate with DIA Live 2017 (finance.yahoo.com)
- Baird Has Reiterated Their Buy Rating on the Stock (latribunadecanarias.com)
- The Stephens Inc. AR Boosts Stake in Icon Plc (ICLR) (cote-ivoire.com)
Several research firms have commented on ICLR. BidaskClub lowered Icon Plc from a “strong-buy” rating to a “buy” rating in a research note on Friday. ValuEngine lowered Icon Plc from a “buy” rating to a “hold” rating in a research note on Wednesday, May 31st. Robert W. Baird cut their price objective on Icon Plc from $107.00 to $97.00 and set an “outperform” rating for the company in a research note on Friday, June 9th. Credit Suisse Group reiterated an “outperform” rating and set a $102.00 price objective (up from $91.00) on shares of Icon Plc in a research note on Tuesday, June 6th. Finally, Jefferies Group LLC reiterated a “hold” rating on shares of Icon Plc in a research note on Thursday, May 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $87.22.
Icon Plc (NASDAQ:ICLR) traded down 0.44% during midday trading on Friday, hitting $92.99. The stock had a trading volume of 264,818 shares. The firm has a market cap of $5.00 billion, a P/E ratio of 19.30 and a beta of 0.60. Icon Plc has a 12-month low of $63.94 and a 12-month high of $98.00. The stock has a 50-day moving average price of $90.86 and a 200 day moving average price of $82.80.
Icon Plc (NASDAQ:ICLR) last issued its quarterly earnings data on Thursday, April 27th. The medical research company reported $1.29 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.27 by $0.02. Icon Plc had a net margin of 16.15% and a return on equity of 28.89%. The business had revenue of $432 million during the quarter, compared to analysts’ expectations of $432.21 million. During the same period last year, the company posted $1.12 EPS. The company’s revenue was up 7.9% on a year-over-year basis. On average, equities analysts anticipate that Icon Plc will post $5.17 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Icon Plc (ICLR) Earning Somewhat Favorable Press Coverage, Report Shows” was originally reported by sleekmoney and is owned by of sleekmoney. If you are viewing this piece of content on another publication, it was stolen and republished in violation of United States & international trademark & copyright legislation. The legal version of this piece of content can be read at https://sleekmoney.com/icon-plc-iclr-earning-somewhat-favorable-press-coverage-report-shows/1916786.html.
About Icon Plc
ICON public limited company is a contract research organization (CRO), which is engaged in providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies.
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/icon-plc-iclr-earning-somewhat-favorable-press-coverage-report-shows/1916786.html
Receive News & Ratings for Icon Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon Plc and related companies with MarketBeat.com's FREE daily email newsletter.